Ironwood appoints Ronald Silver interim CFO; approves $12,250 monthly fee and 25,000 RSUs

IRONWOOD PHARMACEUTICALS INC

Monthly interim assignment fee of $12,250 approved for interim CFO Silver effective May 19, 2026.
Silver received 25,000 RSUs vesting 50% each anniversary over two years.
Fee and RSUs remain until permanent CFO appointed or interim assignment ends.
Silver also serves as SVP, Corporate Controller and Chief Accounting Officer.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Ronald Silver

interim chief financial officer

IRWD · IRONWOOD PHARMACEUTICALS INC

Effective: 2026-05-19
Filed: May 21, 2026, 4:05 PM ET

On May 19, 2026, in connection with Mr. Silver’s new role as the Company’s interim chief financial officer and principal financial officer, the Committee approved a monthly interim assignment fee of $12,250

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ronald Silver was appointed as interim chief financial officer at IRONWOOD PHARMACEUTICALS INC.

Action: appointed
Role: interim chief financial officer

Exact text from the filing

On May 19, 2026, in connection with Mr. Silver’s new role as the Company’s interim chief financial officer and principal financial officer, the Committee approved a monthly interim assignment fee of $12,250

View on SEC.gov

IRONWOOD PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-26-065140

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.